News Website

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - Physician's Weekly

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer Physician's Weekly

Published: June 10, 2025, 6:31 a.m.

Read Full Article

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - HealthDay

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer HealthDay

Published: June 9, 2025, 2:50 p.m.

Read Full Article

AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News - GuruFocus

AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:46 p.m.

Read Full Article

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace

Published: June 9, 2025, 12:43 p.m.

Read Full Article

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:18 p.m.

Read Full Article

Phase 3 Trial Launches ENHERTU as First-Line Endometrial Cancer Treatment | CGEN Stock News - Stock Titan

Phase 3 Trial Launches ENHERTU as First-Line Endometrial Cancer Treatment | CGEN Stock News Stock Titan

Published: June 9, 2025, noon

Read Full Article

Obesity-induced inflammation plays a crucial role in endometrial cancer... - researchgate.net

Obesity-induced inflammation plays a crucial role in endometrial cancer... researchgate.net

Published: June 9, 2025, 1:53 a.m.

Read Full Article

Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer - The ASCO Post

Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer The ASCO Post

Published: June 6, 2025, 5:43 p.m.

Read Full Article

Genmab progresses with reduced dose of Rina-S in endometrial cancer studies - MSN

Genmab progresses with reduced dose of Rina-S in endometrial cancer studies MSN

Published: June 6, 2025, 12:53 a.m.

Read Full Article

NHE7 drives endometrial cancer progression by delaying senescence through cAMP/CREB/GRIN2B axis-mediated Ca²⁺ influx - Nature

NHE7 drives endometrial cancer progression by delaying senescence through cAMP/CREB/GRIN2B axis-mediated Ca²⁺ influx Nature

Published: June 5, 2025, 9:33 p.m.

Read Full Article

Latest Articles

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - Physician's Weekly

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - HealthDay

AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

Phase 3 Trial Launches ENHERTU as First-Line Endometrial Cancer Treatment | CGEN Stock News - Stock Titan

Obesity-induced inflammation plays a crucial role in endometrial cancer... - researchgate.net

Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer - The ASCO Post

Genmab progresses with reduced dose of Rina-S in endometrial cancer studies - MSN

NHE7 drives endometrial cancer progression by delaying senescence through cAMP/CREB/GRIN2B axis-mediated Ca²⁺ influx - Nature

Subscribe to Our Newsletter